StockNews.AI
KURA
StockNews.AI
181 days

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

1. Kura Oncology will report Q4 2024 results on February 26, 2025. 2. Ziftomenib is the first therapy with Breakthrough Therapy Designation for R/R NPM1-mutant AML. 3. Kura entered partnership with Kyowa Kirin for ziftomenib development. 4. Enrollment in Phase 2 trial for ziftomenib in AML was completed.

Earnings
+2.19%Current Return
VS
-0.45%S&P 500
$7.98502/19 07:35 AM EDTEvent Start
$8.1602/20 02:01 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming quarterly results and strategic collaborations point to potential growth, as demonstrated by past collaborations enhancing stock value.

How important is it?

The report reflects financial health and strategic direction, which can influence investor sentiment.

Why Short Term?

The Q4 results could lead to immediate stock price movement, similar to past earnings reports causing volatility.

Related Companies

KYOWFAMGNBMY
February 19, 2025 07:30 ET  | Source: Kura Oncology, Inc. SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the conference ID: KURAQ4. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (the “FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn. Contacts Investors:Patti BankManaging Director(415) 513-1284patti.bank@icrhealthcare.com Media:Alexandra WeingartenAssociate Director, Corporate Communications & Investor Relations(858) 500-8822alexandra@kuraoncology.com

Related News